Focus

Rare Disease Investors: Angels and VC Firms

The RaiseHunt database lists 91 Rare Disease investors: 17 angel investors and 74 people at 30 firms. Most list Series A and Seed among their stages; the largest hubs are New York, Boston and Paris.

Strongest in New York, Boston and Paris

Common stages: Series A and Seed

91
Rare Disease investors
17
Angel investors
74
People at VC/PE firms
30
Firms tagged

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

91 Rare Disease investors

Showing 1-20

Filters
David Jin
David Jin

angel investor

New York, United States
Angel
Healthcare
View profile
Mark Stoner
Mark Stoner

angel investor and operator angel

San Francisco, United States
AngelOperator angel
AIFinTech
View profile
Thomas Zheng
Thomas Zheng

angel investor and operator angel

San Diego, United States
AngelOperator angel
AIHealthcare
View profile
Roger Jeffs
Roger Jeffs

angel investor and operator angel

Raleigh, United States
AngelOperator angel
Healthcare
View profile
Peter Hecht
Peter Hecht

angel investor and operator angel

Cambridge, United States
AngelOperator angel
Healthcare
View profile
John Glasspool
John Glasspool

Venture Partner

Boston, United States
Venture capital
AIHealthcare
View profile
Geeta Vemuri
Geeta Vemuri

Founder

Boston, United States
Venture capital
AIHealthcare
View profile
Callum Booker
Callum Booker

Founder

Austin, United States
Syndicate / Angel groupVenture capital
AICommerce
View profile
Sunny Reddy
Sunny Reddy

Principal

New York, United States
Venture capital
Healthcare
View profile
Preston Noon
Preston Noon

Co-Founder

Boston, United States
Venture capital
AIHealthcare
View profile
Danyin P.
Danyin P.

Chiesi Group

Amsterdam, Netherlands
Corporate VC
AIHealthcare
View profile
Ross Lindsay
Ross Lindsay

Investor

Cambridge, United Kingdom
Corporate VC
Healthcare
View profile
Nurdan Aydin
Nurdan Aydin

Investment Partner

Holbæk, Denmark
Corporate VC
Healthcare
View profile
Niklas Benedikt Grimm
Niklas Benedikt Grimm

Researcher

Germany
Corporate VC
Healthcare
View profile
Jason Curry
Jason Curry

angel investor and operator angel

Pittsburgh, United States
AngelOperator angel
FinTechHealthcare
View profile
Andrew Kaplan
Andrew Kaplan

Board Observer

Boston, United States
Corporate VCPrivate equity
AICommerce
View profile
Fernando Castillo Lasheras
Fernando Castillo Lasheras

angel investor and operator angel

Bilbao, Spain
AngelOperator angel
Healthcare
View profile
John McNamara
John McNamara

Managing Director, Investments

San Francisco, United States
Family Office
ClimateEducation
View profile
Daniel Burke
Daniel Burke

Investor

Cleveland, United States
Accelerator
Healthcare
View profile
David Lee
David Lee

Chief Investment Officer

Palo Alto, United States
Family Office
ClimateEducation
View profile

Frequently asked questions

How many Rare Disease investors are on RaiseHunt?

RaiseHunt currently lists 91 Rare Disease investors.

Are Rare Disease investors angels or funds?

Both. 17 are angel investors putting in their own money, and 74 are people making investment decisions at 30 firms.

Where are most Rare Disease investors based?

The largest concentrations are in New York, Boston and Paris.

What stage do Rare Disease investors invest at?

Most list Series A and Seed among the rounds they take part in.

How do I contact Rare Disease investors?

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Is the list of Rare Disease investors free to browse?

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

Do Rare Disease investors only back Rare Disease companies?

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

What if no Rare Disease investor replies?

Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.

What is the difference between an angel investor and a VC fund?

An angel invests their own money and can decide alone, which usually makes the process shorter. A fund invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a fund once there is more to show.

How many Rare Disease investors should I contact?

Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a list of a handful of perfect names tends to stall. Build a long list, sort it by how well each one matches what you are building, and work down it in batches rather than sending everything at once.

What should I have ready before reaching out?

A short deck, a one-paragraph description of what you do and who it is for, and a clear number for how much you are raising. Investors read the first two lines before they decide whether to open the deck, so those lines matter more than the rest of the document.

Does a warm introduction still matter?

It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what someone has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.

Data: RaiseHunt investor dataset · Snapshot 27 August 2026 · How this data is built · Report a correction or request removal